Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MLYS
STRONG SELLMineralys Therapeutics, Inc. · Healthcare · United States · $2.4B · Avg Vol: $36M/d
COMPANY DESCRIPTION
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for hypertension and cardiorenal diseases, with its lead candidate lorundrinerant. Its proprietary drug candidate targets a novel mechanism of action (aldosterone synthase inhibition) for uncontrolled hypertension, addressing a significant unmet medical need. The company is developing a potential first-in-class treatment that could offer a new therapeutic option for patients with high blood pressure and related conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 121.4M | — |
| EPS | -3.77 | -0.34 | -0.93 | -3.66 | -2.29 | — | -1.97 | -2.24 | -2.10 | — |
| Shares | — | 88.2M | 88.2M | 49.8M | 81.5M | -7.5% | 88.2M | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — | — |
| Equity | — | -52.3M | 241.2M | 191.3M | 646.7M | 63.8% | — | — | — | — |
| Op CF | — | -29.2M | -81.2M | -166.3M | -142.4M | — | -136.4M | — | — | — |
| Inv CF | — | -21.8M | -160.5M | 115.0M | -389.8M | — | — | — | — | — |
| Fin CF | — | 128.0M | 203.2M | 116.1M | 591.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MLYS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc.(you) | $2.4B | 16 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
| BEAM | Beam Therapeutics Inc. | $2.6B | 17 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 16 | STRONG SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| BHVN | Biohaven Ltd. | $2.2B | 20 | STRONG SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 18 | STRONG SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
| KLRA | Kailera Therapeutics, Inc. | $2.3B | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%